Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Clinical trial NCT04589650 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04589650
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-19
- Primary completion
- 2024-03-20
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.